Latest News

Results from the ZeNix trial show that the BPaL combination of drugs remains effective against highly drug resistant tuberculosis (TB) with reduced dosage or duration of the linezolid part of the regimen.
The anti-HIV drug dolutegravir, given in combination with other anti-HIV drugs, improves outcomes for babies and young children living with HIV, compared to standard anti-HIV treatment combinations.
Launch of UNITE4TB partnership marks a new era in Tuberculosis treatment development
New results confirm the benefit of arthritis drugs in hospitalised patients with COVID-19
This Friday marks the beginning of the 2021 ASCO Annual meeting, where MRC Clinical Trials Unit at UCL will be presenting results from colorectal and prostate cancer trials.